摘要
氯吡格雷是临床应用最广泛的抗血小板药物之一，但其临床疗效存在明显的个体差异，除临床因素外，遗传因素为另一个导致氯吡格雷疗效个体差异性的因素。氯吡格雷血小板高反应性（HTPR）相关基因的突变频率存在显著的种族差异，东亚人群的相关基因突变频率高于西方人群。目前研究表明，东亚人群发生氯吡格雷治疗期间HTPR的比例为20％-30％，高于西方人群，且CYP2C19＊和＊3为HTPR的独立风险因素。通过增加氯吡格雷剂量，三联抗血小板治疗或换用新型P2Y12受体拮抗剂等策略可改善患者HTPR，并降低心血管事件的发生风险。
Clopidogrel is one of the most widely used antiplatelet drugs, which plays the significant individual differences in clinical effect. Besides clinical factor, genetic factor is another important part, which influences individual differences. Gene mutation frequency of clopidogrel high on- treatment platelet reactivity （HTPR） holds significant ethnic differences. The related gene mutation in East Asian populations is more frequently than that in west populations. Recent studies have indicated that the incident of HTPR of clopidogrel in East Asian was 20% - 30%, which was higher than that in Westerns. CYP2C19＊2 and CYP2C19＊3 are considered as the independent risk dosage, triple antiplatlet treatment of cardiovascular events. factor of HTPR. Several optimal and novel P2Y12 receptor usage, strategies, such as an increased clopidogrel can improve the HTPR and reduce the risk
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2016年第3期153-157,共5页
Chinese Journal of New Drugs and Clinical Remedies
基金
上海医院药学科研项目(2014-YY-01-20)
关键词
氯吡格雷
多态性
单核苷酸
亚洲大陆世系人群
远东
血小板高反应性
基因多态性
clopidogrel
polymorphism, singte nucleotide
Asian continental ancestry group
far east
high on-treatment platelet reactivity
gene polymorphism
